Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2837 | Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances Wiki | 0.71 |
| drug2916 | Placebo Wiki | 0.04 |
Navigate: Correlations HPO
There is one clinical trial.
The primary objective of this study is to evaluate the safety and efficacy of intravenous (IV) infusion of ulinastatin compared to placebo with respect to time to recovery, disease severity, need for ventilator support, and mortality in patients with COVID 19.
Description: Time to recovery, defined as attaining a score of 6, 7, or 8 on the COVID-19 disease severity scale, an 8 point ordinal scale used in the NIH Adaptive COVID-19 Treatment Trial (ACTT; NCT04280705). = Death; = Hospitalized and on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); = Hospitalized and on non-invasive ventilation or high-flow oxygen devices; = Hospitalized and requiring supplemental oxygen; = Hospitalized and not requiring supplemental oxygen but requiring ongoing medical care (COVID-19-related or otherwise); = Hospitalized and not requiring supplemental oxygen and no longer requiring ongoing medical care; = Not hospitalized, limitation on activities and/or requiring home oxygen; = Not hospitalized, no limitation on activities
Measure: Time to recovery Time: Up to 29 daysDescription: COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
Measure: COVID-19 disease severity scale score on Day 8 Time: Day 8Description: COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
Measure: COVID-19 disease severity scale score on Day 15 Time: Day 15Description: COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
Measure: COVID-19 disease severity scale score on Day 22 Time: Day 22Description: COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
Measure: COVID-19 disease severity scale score on Day 29 Time: Day 29Description: For patients requiring mechanical ventilation.
Measure: Duration of mechanical ventilation Time: Up to 29 daysDescription: For patients requiring mechanical ECMO.
Measure: Duration of ECMO Time: Up to 29 daysDescription: For patients requiring non-invasive ventilation
Measure: Duration of noninvasive ventilation Time: Up to 29 daysDescription: For patients admitted to ICU
Measure: Duration of ICU stay Time: Up to 29 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports